EICHOR
● Active Not Recruiting
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Condition: Melanoma · Head and Neck Squamous Cell Carcinoma · Colo-rectal Cancer · Sponsor: Vyriad, Inc.
About this study
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment. (CRC and melenoma cohorts are now closed to new patients)
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (13)
| Saint John's Health Center - John Wayne Cancer Institute (JWCI) | Santa Monica, California, United States | — |
| Yale University | New Haven, Connecticut, United States | — |
| University of Miami | Miami, Florida, United States | — |
| Ochsner Clinic Foundation | New Orleans, Louisiana, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| Billings Clinic Montana Cancer Consortium | Billings, Montana, United States | — |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | — |
| University of Cincinnati Medical Center | Cincinnati, Ohio, United States | — |
| Sanford Cancer Center | Sioux Falls, South Dakota, United States | — |
| Hospital Sao Rafael | Salvador, BR, Brazil | — |
| INCA | Rio de Janeiro, Rio de Janeiro, Brazil | — |
| Hospital Moinhos de Vento | Porto Alegre, Rio Grande do Sul, Brazil | — |
+ 1 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04291105